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1. Introduction 
It is well established, that the appearance of chronic lymphocytic leukemia (CLL), the most 
frequent form of leukemia in adults, in the developed countries, is mainly due to the gradual 
accumulation of malignant clone originated from CD5/CD19/CD23 positive lymphocytes. 
This accumulation results from a dysregulation between proliferation and apoptosis of 
neoplastic cells. In normal lymphocytes these processes are in equilibrium, so that total 
number of these cells in the organism remains stable. It has been known for two decades that 
the accumulation of leukemic lymphocytes in CLL is a consequence of defects of programmed 
cell death, but also, to some extent, of their dysregulated proliferative activity, as shown by the 
blockade of certain CLL lymphocytes in G1 cell cycle phase (Decker et al., 2002). The aim of this 
chapter is to discuss essential abnormalities of CLL cells apoptosis and proliferation which 
contribute to the development of the disease and may determine its clinical course. However it 
must be remembered, that significant majority of experimental data concerning survival and 
apoptosis of CLL cells, especially regarding cytokines, come from in vitro studies, thus it is 
difficult to apply them directly to in vivo situation. 
Numerous studies allowed to establish, that leukemic cells both circulating in the blood and 
residing in lymphoid organs survive in vivo for a very long time, counted in months, due to 
inhibition of their programmed death, but they undergo rapid, spontaneous apoptosis in  
a few days when cultured in in vitro conditions (Collins et al., 1989). It is then plausible that 
the prolonged in vivo lifespan is due to the prosurvival influence of microenvironmental 
factors, in particular to the interactions of malignant lymphocytes with stromal cells (Munk-
Pedersen & Reed, 2004; Deaglio & Malavasi, 2009), and probably to the B cell receptor 
engagement by antigens (Ghia et al., 2008; Burger et al., 2009a). The removal of CLL cells 
from microenvironment to in vitro culture deprives them of indispensable stimuli and leads 
to their rapid apoptosis. Several subpopulations of accessory stromal cells have been 
individualized in the connective tissue. Monocyte-derived CD68+ nurse-like cells, 
mesenchymal stromal cells and follicular dendritic cells seem to play a particularly 
important role in this process (Burger et al., 2009b). 
1.1 Trafficking and homing of CLL cells in microenvironment 
Interaction between chemokine receptor CXCR4 and its ligand CXCL12, formerly known as 
stromal cell-derived factor-1 (SDF-1), plays a crucial role in the homing of malignant 
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lymphocytes within host niches of the microenvironment (Burger & Kipps, 2006). Stromal cells 
and nurse-like cells constitutively secrete CXCL12, what is essential for retention of 
hematopoietic stem cells, physiologically expressing CXCR4, inside bone marrow. CLL cells, 
which usually strongly express CXCR4 independently from the type of the disease, make use 
of CXCR4/CXCL12 axis to remain in a favourable environment (Broxmeyer et al., 2005). 
Analogous mechanism acts through receptor CXCR5, present in high density on leukemic 
lymphocytes and ligand CXCL13 synthesized by nurse-like cells in lymphatic nodes and  
a spleen (Burkle et al., 2007). CLL cells also overexpress CCR7, a receptor interacting with 
chemokines CCL19 and CCL21. The intensity of this ligation is additionally regulated by 
atypical, non-signalling receptors CRAM and CCX-CKR (Catusse et al., 2010) and correlates 
with infiltration of lymphatic nodes, a process which requires a cooperation of ǂ4 integrin (Till 
et al., 2002). Higher expression of CCR7 has been related to more advanced stage of the disease 
and the presence of lymphadenopathy (Ghobrial et al., 2004). The role of another chemokine 
receptor, CXCR3, is relatively poorly understood. Its expression on malignant lymphocytes 
considerably varies between patients but remains stable over time in individual cases, and 
surprisingly – lower level of CXCR3 is strongly associated with Rai stages III and IV, diffuse 
pattern of the bone marrow infiltration and shorter overall survival (Ocana et al., 2007). 
Another mechanism involved in the adhesion of CLL cells to components of 
microenvironment concerns integrins – glycoproteins composed of ǂ and ǃ subunits, 
mediating cell-to-cell and cell-to-matrix junction. The ǂ4ǃ1 integrin called VLA-4 or CD49d is 
variously expressed on malignant lymphocytes and acts as a receptor for fibronectin and 
vascular cell adhesion molecule-1 (VCAM-1 or CD106), cooperating with chemokine receptors 
in adhesion of these cells to stromal cells and extracellular matrix. Moreover, high expression 
of VLA-4 correlates with more advanced stage of the disease and shorter overall survival, 
revealing value as an independent negative prognostic factor (Gattei et al., 2008). 
1.2 Reversible influence of CLL cells on the microenvironment 
Malignant clone of CLL cells not only uses microenvironmental stimuli, but also influences 
neighbouring tissues in order to increase attained benefits. Communication between 
neoplastic lymphocytes and their microenvironment may be executed by microvesicles – 
detached fragments of malignant cells cytoplasm surrounded by a cell membrane, which are 
able to fuse nearby cells carrying there numerous proteins and lipids thus exerting impact 
profitable for a growth and progression of leukemia. A particular mechanism described in 
CLL concerns transmission of agents stimulating stromal cells to produce vascular endothelial 
growth factor (VEGF), what leads to enhanced angiogenesis in the bone marrow (Ghosh et al., 
2010). Malignant lymphocytes can also actively attract accessory cells, particularly T 
lymphocytes and monocytes, thus accumulating them in microenvironment, what modifies 
local immune response in favour of the neoplasm progression. Main factors secreted by CLL 
cells for this purpose are chemokines CCL3 and CCL4, synthesized after B-cell receptor 
stimulation (Sivina et al., 2011), and CCL22, produced after CD40 ligation (Ghia et al., 2002). 
2. Apoptosis 
Processes leading to a programmed cell death can be initiated by either intracellular or 
extracellular signals. Accordingly, two pathways of apoptosis are distinguished: intrinsic, 
otherwise called “mitochondrial” and extrinsic, triggered by death receptors signalling.  
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A wide range of intracellular factors, like DNA damage leading to expression of p53 protein, 
hypoxia, or growth factors deficiency activate an intrinsic pathway influencing the 
transcription of Bcl-2 family proteins what leads to an increased release of cytochrome c 
from mitochondria to cytosol. Thereafter, cytochrome c together with Apaf-1 (apoptotic 
protease activating factor 1), inactive procaspase-9 and dATP form a complex called 
apoptosome, which activates caspase-9. This enzymatic complex launches caspase cascade, 
what causes nuclear condensation, DNA fragmentation, membrane blebbing and finally 
leads to the cell death. A protein named apoptosis inducing factor (AIF), released from 
mitochondrion in the same circumstances as cytochrome c, enters the nucleus and results in 
a cell death without cooperation of caspases. An extrinsic pathway of apoptosis is initiated 
by activation of several membrane receptors including Fas and TNFǂR by their respective 
ligands. Activated receptors trigger caspase cascade via protein called Fas associated death 
domain (FADD), which contains domain activating procaspase-8, what leads to cell death. 
2.1 Intracellular pathways of apoptosis 
Human lymphocytes, as all eukaryotic cells, are equipped with a complicated machinery 
serving to execute an extracellular or intracellular suicide signal in response to various 
situations which necessitate cell its death, e.g. unrepairable DNA damage, penetration of  
a virus into a cell, or neoplastic transformation. Numerous anomalies disturbing this 
machinery were described in CLL lymphocytes. Those anomalies result in ineffective 
apoptosis of malignant cells and consequently in their gradual accumulation in blood and 
lymphoid tissue, thus influencing a clinical course of the disease. 
2.1.1 Bcl-2 protein family 
The Bcl-2 family is a very conservative class of proteins, detected in a wide range of 
eukaryotic organisms, from simple nematodes, like Caenorhabditis elegans, to mammalians. 
Its fundamental role is to control the mitochondrial pathway of apoptosis, by regulation of 
the permeability of mitochondrial membranes. Bcl-2 and Bcl-xL are principal antiapoptotic 
proteins of this family. They are located in the outer mitochondrial membrane where they 
inhibit the release of the cytochrome c from intermembrane space and the creation of the 
apoptosome, so that the activation of caspase-9 is impaired. As a result of prosurvival 
activity of Bcl-2 and Bcl-xL, caspase cascade is not activated and cells are protected from 
apoptosis. Mcl-1 is another important prosurvival protein in this group, structurally 
different from previous ones, localized predominantly in endoplasmic reticulum and 
nuclear membrane, interfering with other Bcl-2 agents and inhibiting the cytochrome c 
release. Proapoptotic members of Bcl-2 family can be divided into two subgroups, 
depending on number of repeated homological domains called “BH” in their structure: 
“multidomains” (Bax, Bak, Bok), possessing four domains called BH1, BH2, BH3, BH4, and 
“BH3-only” (Bim, Bad, Bid, Puma and Noxa). Those proteins can be activated by various 
signals, like growth factors deprivation, or p53 induced by DNA damage e.g. after radiation 
or cytotoxic therapy. They deactivate Bcl-2 and Bcl-xL, and support cytochrome c release, 
thus promoting caspase dependent programmed cells death. In some situations Bid 
undergoes activation by Fas receptor-induced cleavage and by caspase-8, then it promotes 
cytochrome c release and triggers the caspases cascade. Therefore it connects both apoptotic 
pathways: intrinsic and extrinsic one. (Packham & Stevenson, 2005) 
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Numerous abnormalities of Bcl-2 family proteins expression were observed in CLL cells and 
it is generally accepted, that shifted balance between different members of that family 
towards antiapoptotic ones plays a crucial role in prolonging of neoplastic cells in vivo 
survival. Relatively high expression of Bcl-2 probably because of hypomethylation of its 
gene were detected in cytoplasm of malignant lymphocytes (Hanada et al., 1993; Robertson 
et al., 1996). An elevated Bcl-2/Bax ratio was found to be related to chemoresistance and 
worse prognosis in this disease (Aguilar-Santelises et al., 1996; Molica et al., 1998; Thomas et 
al., 2000). Yet another observation proves an importance of high Bcl-2 and low Bax levels in 
programmed cell death inhibition: CLL cells which underwent apoptosis induced by an 
external factor, e.g. resveratrol, revealed remarkably decreased Bcl-2/Bax ratio (Podhorecka 
et al., 2011). Increased proteosomal degradation of Bax is considered as a cause of its lower 
expression (Agraval et al., 2008). Data concerning clinical significance of a decreased Bax 
level as the only disturbance are somewhat controversial, since some studies suggest its 
negative prognostic role (Bannerji et al., 2003), while some other ones do not confirm it 
(Faderl et al., 2002). Increased expression of prosurvival protein Mcl-1 was detected in 
approximately half of CLL cases, what is thought to inhibit apoptosis and hamper the 
therapeutic effect of chlorambucil as well as fludarabine (Kitada et al., 1998; Pepper et al., 
2008), and rituximab (Awan et al., 2009). Moreover, low expression of MCL-1 gene was 
correlated with prolonged overall survival in the disease (Veronese et al., 2008). Some other 
observations suggest that upregulated expression of Mcl-1 plays a crucial role in a protective 
influence of microenvironmental factors on leukemic cells (Pedersen et al., 2002). Less is 
known about other Bcl-2 family members. It was shown that simultaneous deficiency of Bax 
and Bak proteins was related to cells resistance to majority of proapoptotic signals (Wei et 
al., 2001). Noxa, a protein inducing programmed cells death, is paradoxically excessively 
expressed in CLL lymphocytes (Mackus et al., 2005). Significance of that phenomenon 
remains unclear, but it was suggested, that leukemic cells in lymphatic nodes expressed low 
levels of Noxa, due to proliferative stimuli of microenvironment. In the absence of these 
signals in circulation Noxa becomes upregulated, but not strongly enough to overcome an 
apoptosis blockade of highly expressed Bcl-2 (Smit et al., 2007). 
2.1.2 Role of p53 in activation of apoptosis 
One physiological defense mechanism, aimed at the genome integrity protection, is based 
on induction of apoptosis when cellular DNA damage becomes irreparable. A key role in 
that phenomenon is played by p53, a transcription factor which expression is induced by 
DNA damage. This factor stimulates the expression of p21Cip1/WAF1 – universal inhibitor of 
cyclin-dependent kinases – cyclin complexes, which blocks the cell cycle progression and 
allows the cell to repair the genetic material. When this repair cannot be completed, p53 
enhances the transcription of genes encoding Bax, Puma and Noxa – proapoptotic members 
of Bcl-2 family, thus initiating the mitochondrial pathway of programmed cell death 
(Vousden & Lu, 2002). In addition, recent studies suggest, that p53 acts not only as  
a transcription factor, but is also able to induce apoptosis through direct binding to Bcl-2 
protein, deactivating it, what subsequently activates Bax, Puma and triggers caspase cascade 
(Chipuk et al., 2004; Steele et al., 2008). Approximately 10% to 15% of CLL patients reveal 
structural aberrations or point mutations in locus 17p13, containing TP53 (gene encoding 
p53), what results in an improper function of this protein and defective apoptosis of 
leukemic cells in response to alkylating agents and purine analogues. Those disturbances 
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have a profound influence on the clinical picture of CLL. The presence of 17p deletion or 
TP53 mutations is associated with higher clinical stage of the disease, shorter treatment-free 
survival (Dohner et al., 2000), more aggressive clinical course, shorter progression-free and 
overall survival (Rossi et al., 2009). It should be mentioned, that double-strand DNA breaks 
activate p53 through phosphorylation and dephosphorylation of single aminoacids of its 
chain by ATM protein (Johnson et al., 2009). That is why the inactivation of ATM gene, 
located in locus 11q22.3 to 11q23.1, leads to p53 functional deficiency. Therefore ATM 
mutations, resulting mainly from 11q22 – q23 deletions and detected in about 20% of CLL 
patients, are also considered as negative prognostic factors in the disease, although of lesser 
importance than 17p aberrations and TP53 mutations (Dohner et al., 2000; Austen et al., 
2005). 
2.1.3 NF-κB signal transduction pathway 
Transcription factor called nuclear factor kappa-B (NF-κB) is a homo- or heterodimeric 
protein composed of subunits belonging to Rel family, which contains following members 
identified so far: RelA, RelB, c-Rel, p50 and p52. In the inactive state NF-κB is sequestrated 
in the cytosol by binding to one of its specific inhibitors: IκB-ǂ, IκB-ǃ, IκB-Ǆ, IκB-ε, Bcl-3, 
p100 or p105, called collectively “IκB” (Zheng et al., 2011). Activation of NF-κB pathway 
starts by the interaction of a specific ligand with a receptor activator of NF-κB (RANK), 
which belongs to a family of TNF-ǂ receptors. Numerous factors can induce NK-κB: tumor 
necrosis factor ǂ (TNF-ǂ), interleukin 1ǃ (IL-1ǃ), osteoprotegerin, ionizing radiation, 
oxidative stress, or bacterial endotoxins (Vallabhapurapu & Karin, 2009). Stimulated RANK 
activates a group of kinases called IKK, which phosphorylate IκB liberating it from NF-κB. 
RANK is also able to activate NF-κB through a specific NF-κB inducing kinase (NIK). When 
activated, NF-κB enters the nucleus, where it induces the expression of numerous important 
antiapoptotic genes encoding such proteins as: prosurvival members of Bcl-2 family (Bcl-2, 
Bcl-xL), cellular inhibitors of apoptosis (IAP family) deactivating caspases, FLICE-like 
inhibitory protein (FLIP) blocking Fas-associated death domain (FADD), or TNF receptor-
associated factor (TRAF), mediating antiapoptotic signals (Fan et al., 2008). 
CLL malignant cells show higher constitutive activation of NF-κB than normal lymphocytes 
(Furman et al., 2000). The impulses such as: CD40 ligation, induction of B-cell receptor (BCR), 
IL-4, BAFF (B-cell activating factor) or APRIL (a proliferation inducing ligand) were reported 
to stimulate NF-κB in CLL cells and to antagonize physiological pathways of a programmed 
cell death. NF-κB expression was reported to show individual variations and may correlate 
with tumor burden and lymphocytes doubling count, confirming the importance of this 
signalling pathway in the development and progression of the disease (Hewamana et al., 
2008). Currently it is generally accepted that NF-κB is one of the most important transducers of 
external stimuli, keeping CLL cells alive with blocked apoptosis (Cuni et al., 2004). 
2.1.4 PI3K/Akt survival pathway 
It is commonly acknowledged that cells need a permanent stimulation with appropriate growth 
factors to survive. A signalling cascade of the phosphatidylinositide 3’-OH kinase (PI3K) and 
Akt kinase is thought to be, at least partially, responsible for transduction of prosurvival 
extracellular stimuli. Their binding to membrane ligands results in displacement of PI3K to the 
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inner surface of a cell membrane. PI3K phosphorylates membrane phosphoinositides, which 
recruit Akt from cytosol to plasma membrane and change its conformation into more accessible 
as a substrate for specific 3-phosphoinositide-dependent protein kinases (PDK-1 and PDK-2). 
Thereafter PDKs activate Akt by phosphorylation. Five targets of Akt antiapoptotic action on 
intracellular machinery of a programmed cell death were identified. The first one is Bad – 
proapoptotic member of Bcl-2 family. Akt phosphorylates Bad inactivating it, thus preventing 
interaction between Bad and Bcl-xL. Bcl-xL liberated from Bad performs its physiological 
prosurvival role of blocking cytochrome c release from mitochondria. The second one is 
caspase-9 – an important link between apoptosome and effector caspase-3. Akt inactivates it 
and thus interrupts caspase cascade. The third site of Akt’s influence on apoptosis is its 
activating action on IKKs – kinases inducing antiapoptotic pathway of NF-κB, as described 
above in appropriate section of this chapter. The fourth target of Akt is so called Forkhead 
family of transcription factors, which regulates expression of several genes important for 
apoptosis, including Fas ligand gene. Akt inactivates Forkhead family members by 
phosphorylation, thus reducing their proapoptotic effect (Datta et al., 1999). XIAP (X-linked 
inhibitor of apoptosis protein), one of most potent inhibitors of caspases, is the fifth target of 
Akt. XIAP phosphorylated by Akt becomes more resistant to ubiquitination and proteolytic 
degradation, therefore its prosurvival influence becomes prolonged (Dan et al., 2004). 
Stimulation with microenvironmental, non-malignant, bystander cells results in a high 
activity of PI3K/Akt pathway in CLL lymphocytes. Those prosurvival signals reach 
leukemic cells through various membrane receptors, like B-cell receptor, CD40 (Cuni et al., 
2004), or, described recently, CD160 – membrane protein not present in normal B 
lymphocytes, but expressed on leukemic ones, which has the property of activating 
PI3K/Akt pathway (Liu et al., 2010). It is supposed, that enhanced activity of Bcl-xL and 
NF-κB is the most important way of Akt’s influence on cell apoptosis in CLL. Additionally, 
recent studies suggest that sustained activation of Akt results also in increased expression of 
Mcl-1 in leukemic cells, what shifts the balance between members of Bcl-2 family towards 
the prosurvival ones (Longo et al., 2008). 
2.1.5 Ambiguous role of JNK in apoptosis 
The c-Jun N-terminal protein kinase (JNK) belongs to the family of the mitogen activated 
protein kinase (MAPK) and is involved in a regulation of cellular apoptosis, responding to a 
variety of extracellular signals. Despite extensive studies published so far, the exact role of 
JNK in apoptosis remains unclear. Some studies suggested its proapoptotic function (Davis, 
2000), some other showed its antiapoptotic activity (Yu et al., 2004), and other ones did not 
prove any impact at all of this factor on the programmed cell death (Lin, 2003). Probably a 
real effect of JNK on apoptosis depends on the type of investigated cells and stimuli tested. 
FasL and TNF-ǂ may activate JNK and lead to the suppression of Bcl-2 and subsequently 
inhibition of the apoptosis. Some studies suggest that prior inhibition of NF-κB may be 
required for this antiapoptotic action of JNK (Liu & Lin, 2005). Moreover, studies performed 
on pro-B hematopoietic cells displayed a suppression of a programmed cell death via 
inactivation of Bad – proapoptotic member of Bcl-2 family – through its phosphorylation by 
JNK in response to interleukin-3 stimulation (Yu et al., 2004). As it was presented in one 
study, B-cell receptor stimulation probably did not reveal any effect on the activity of JNK 
pathway in CLL cells (Petlickovski et al., 2005). 
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2.1.6 Caspase cascade 
Majority of pathways transducing extra- and intracellular proapoptotic signals converge 
toward caspases, a family of cysteine proteases, main executors of apoptotic processes. 
These proteins localize in cytosol as inactive zymogens and after induction of apoptosis they 
form a proteolytic chain of consecutively activated enzymes, which is called a caspase 
cascade. Generally, two classes of caspases are distinguished: initiator and effector ones. 
Initiator caspases (caspase-8, 9, 10 and 12) transduce signals from apoptotic pathways, 
cleave and activate effector ones (caspase-3, 6 and 7) (Riedl & Shi, 2004). The intrinsic 
pathway of apoptosis leads to the formation of apoptosome, which is, as already mentioned, 
a complex containing Apaf-1, cytochrome c liberated from mitochondria, procaspase-9 and 
dATP. Apoptosome activates caspase-9 which subsequently activates effector caspase-3 and 
caspase-6. Induction of the extrinsic pathway results in caspase-8 and caspase-10 activation 
through FADD, thereafter both initiator caspases mentioned above activate the effector 
caspase-3. Afterwards caspase-3 activates downstream effector caspase-7. Finally, main 
effector caspase-3, in cooperation with caspase-6 and 7, cleaves a variety of proteins, like 
laminA, actin, gas2, what causes cell shrinkage and membrane blebbing. Additionally, 
caspase-3 inactivates ICAD (inhibitor of CAD), what liberates CAD (caspase activated 
DNAse) and results in DNA fragmentation and nuclear chromatin condensation. All these 
processes finally lead to cell death (Logue & Martin, 2008). 
The function of caspase cascade is controlled by a group of cysteine proteases, called IAP 
(inhibitor of apoptosis), containing XIAP, IAP1, IAP2, survivin and livin. They bind and 
potently inhibit caspase-3, 7 and 9, stopping the cascade regardless of pathway of induction 
– intrinsic or extrinsic one (Deveraux & Reed, 1999). The activity of IAP family proteins may 
increase in response to stimulation by various antiapoptotic signals which serve as effectors 
of specific pathways. For example, one of antiapoptotic activities of Akt is mediated through 
XIAP, since Akt phosphorylates XIAP, making it more resistant to proteasome-mediated 
degradation (Dan et al., 2004). FLIP (FLICE-like inhibitory protein), existing in two variants: 
c-FLIPS and c-FLIPL, represents another control point of caspases activation. It contains  
a fragment interacting with death domain motif of FADD and simultaneously prevents 
activation of caspase-8 and 10, thus blocking Fas receptor signalling pathway and inhibiting 
programmed cell death (Irmler et al., 1997). However a physiological function of c-FLIPL is 
not fully explained, since recent reports suggested its role in activation of caspase-8 
(Boatright et al., 2004). 
CLL cells do not differ significantly from normal lymphocytes regarding to the expression of 
caspase family proteins. Nevertheless, as apoptosis inhibition is thought to be principal 
mechanism of malignant lymphocytes accumulation, so efforts to induce caspase-dependent 
programmed cell death are evident therapeutic direction. Indeed, caspase activation may be 
used as a surrogate biomarker of successful induction of apoptosis in leukemic cells by 
various chemotherapeutic drugs. A choice of caspase-3 activity assessment for this purpose 
is quite obvious, in view of central effector role of this protein in execution of death signals 
deriving from variety of pathways. Starting from the oldest drugs, chlorambucil is thought 
to induce expression of caspase-3 and apoptosis in CLL cells (Brajuskovic et al., 2004). The 
same phenomenon is observed for newer chemotherapeutics, like fludarabine (Stoetzer et 
al., 1999) and a monoclonal antibody anti-CD20 – rituximab (Byrd et al., 2002). 
Alemtuzumab, a monoclonal antibody anti-CD52, another immunochemotherapeutic agent 
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used in CLL treatment, was not reported to involve caspases pathway, but induces 
apoptosis through a non-classical, caspase-independent pathway (Mone et al., 2006). The 
latter mechanism may also represent another possible mode of action of rituximab 
(Stanglmaier et al., 2004). 
2.1.7 Caspase-independent programmed cell death 
More than ten years ago an observation was published that cells were capable to undergo 
apoptosis even when caspases expression was suppressed. This finding pointed out to the 
existence of caspase-independent mechanisms leading to a programmed cell death (Susin et 
al., 2000). However regardless of numerous studies, caspase-independent cell death still 
remains poorly understood. Currently apoptosis is classified into three subtypes. Type I, 
named “classical apoptosis”, is the best explored one and covers all processes triggering 
caspase cascade, therefore it is often called “caspase-dependent”. Each signalling pathway 
described earlier in this chapter belongs to type I of apoptosis. Type II of programmed cell 
death is related to increased permeability of mitochondrial membrane, analogically to 
intrinsic pathway of classical apoptosis activation (Kim et al., 2005). Proteins released from 
mitochondrial intermembrane space activate proapoptotic factors other than caspases, like 
calpains, cathepsins and other proteases (Constantinou et al., 2009). AIF (apoptosis inducing 
factor) is the best known among them, it is released from mitochondrion, then enters 
nucleus and initiates chromatin condensation and DNA fragmentation. Morphologically 
this type of apoptosis is characterized by large vacuolization of cytoplasm due to 
appearance of autophagosomes (Tait & Green, 2008). Type III of apoptosis is less explored; it 
resembles cellular necrosis and is defined strictly morphologically, with absence of visible 
nuclear chromatin condensation (Bras et al., 2007). 
There are only single reports concerning caspase-independent apoptosis observed in CLL 
lymphocytes. The mechanism reported so far is triggered by membrane glycoprotein CD47, 
thrombospondin-1-binding member of the immunoglobulin superfamily. Activation of 
CD47 by appropriate ligand leads to activation of serpases which afterwards damage 
cytoskeletal protein called F-actin. Improper function of F-actin results in cell shrinkage 
secondary to cytoskeletal damage, and in translocation of Drp1 (dynamin related protein-1) 
from cytosol to mitochondria, where it disrupts the electron transport chain, therefore 
lowering ATP levels (Barbier et al., 2009). As a result of described mechanisms, disturbances 
in cell architecture and mitochondrial function, but no pronounced chromatin condensation 
are detected in cells undergoing the caspase-independent apoptosis. CLL lymphocytes can 
undergo the caspase-independent programmed cell death even when the classical apoptosis 
is disrupted. It raises hope for discovering new agents able to overcome chemoresistancy to 
classical drugs. Further studies on that phenomenon are thus very promising from a clinical 
point of view. 
2.2 Membrane receptors 
All metazoan cells receive numerous external stimuli determining their fate depending on 
momentary requirements of physiological balance in the organism, keeping them alive, or 
pushing onto a path of a programmed death. These signals are transmitted into cells 
through a multitude of receptors, among which a superfamily of TNF (tumor necrosis 
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factor) receptor is one of the most important. Depending on structure and signalling 
properties, members of TNF receptors family are generally classified into three large groups 
(Dempsey et al., 2003). 
The first one contains: Fas receptor (FasR or CD95), TNF-ǂ receptor 1 (TNF-R1 or CD120a), 
death receptor 3 binding to TWEAK (DR3, TRAMP or LARD), death receptors 4 and 5 
binding to TRAIL (DR4 and DR5). All these proteins possess a characteristic death domain 
in their cytoplasmic tail. After activation of receptors by external ligands their death 
domains interact with corresponding transmitter proteins – FasR, DR4 and DR5 with  
Fas-associated death domain (FADD), while TNF-R1 and DR3 with TNFR-associated death 
domain (TRADD). In the next step the caspase cascade is triggered through a caspase-8 
activation and the cell undergoes apoptosis (Kischkel et al., 2000). 
The second group of TNF receptors superfamily contains: TNF-ǂ receptor 2 (TNF-R2 or 
CD120b), CD40, CD27, CD30, B-cell activating factor receptor (BAFFR), TACI and BCMA 
(receptors recognizing both: BAFF and APRIL – a proliferation inducing ligand), 
lymphotoxin-ǃ receptor (LT-ǃR or CD18), OX40 (CD134), TNF-ǂ receptor 2 related protein 
(TNFR2-RP or TNFRIII), receptor activator of NF-κB (RANK), receptor expressed in 
lymphoid tissues (RELT), herpes virus entry mediator (HVEM), and others, not detected on 
B lymphocytes, like LIGHT receptor (LIGHTR), TROY/Taj, p75 neurotrophin receptor 
(p75NGFR), ectodysplasin-A receptor (EDAR), fibroblast growth factor inducible 14 (Fn14), 
or glucocorticoid-induced tumor necrosis factor receptor (GITR) (Darnay et al., 1999). 
Cytoplasmic tails of these receptors contain various numbers of TIM (TRAF interacting 
motifs) – protein sequences reacting with members of TRAF family (TNF receptor-
associated factor). Activated TRAFs form expanded complexes with TNF receptors, IAPs 
and RIPs (the death domain kinase receptor interacting protein) mediating antiapoptotic 
signals through induction of numerous prosurvival pathways, like NF-κB, PI3K/Akt, JNK, 
ERK (extracellular signal regulated kinase) and others (Xie et al., 2008). Therefore activation 
of TNF family receptors of the second group induces inhibition of apoptosis, what brings us 
to an interesting conclusion, that TNF-ǂ can act in two ways – not only proapoptotically, 
through TNF-R1, but also antiapoptotically, through TNF-R2 (Ihnatko & Kubes, 2008). 
A class of proteins unable to transduce stimuli into intracellular signalling pathways forms 
the third group of TNF receptor family members. Decoy receptor 1 (DcR1 or TRAIL-R3), 
decoy receptor 2 (DcR2 or TRAIL-R4), decoy receptor 3 (DcR3) and TNF receptor 
superfamily members 22 and 23 (TNFRSF22 and TNFRSF23) belong to that group. They 
probably compete with other TNF receptors for their ligands, therefore impeding their 
activation and induction of intracellular signalling pathways (Falschlehner et al., 2007). 
Available data concerning aberrations of the TNF receptors superfamily expression and 
function in CLL lymphocytes are scanty, but some interesting observations were published. 
Fas receptor is distinctly downregulated on leukemic cells (Laytragoon-Lewin et al., 1998) 
and attempts of its upregulation by various factors in vitro are not as efficient as in normal B 
cells (De Fanis et al., 2003). Nevertheless, this is unlikely to be the cause of their resistance to 
Fas-mediated apoptosis, because eliciting high FasR expression on a surface of CLL 
lymphocytes does not restore their susceptibility to that way of a programmed cell death 
(Romano et al., 2005). Moreover it seems that the expression of FasR on leukemic cells does 
not have prognostic significance to clinical course of the disease (Hjalmar et al., 2002). CD40 
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is strongly expressed both on CLL cells and normal B lymphocytes, without significant 
difference between them. Activation of CD40 on leukemic cells by its specific ligand CD40L 
(otherwise called CD154) induces expression of proapoptotic FasR, but at the same time it 
strongly activates prosurvival NF-κB pathway. As a result, antiapoptotic effect of CD40 
activation prevails in CLL cells (von Bergwelt-Baildon et al., 2004). In addition it has been 
observed that ligation of CD40 reduces the efficacy of apoptosis induction by fludarabine in 
CLL lymphocytes in vitro (Romano et al., 1998). CD27 is considered as a marker of memory 
B cells and, when activated by CD70, it leads to plasma cell differentiation (Agematsu et al., 
2000). Its expression on a surface of CLL cells does not differ significantly from normal 
lymphocytes, but serum levels of soluble CD27 are higher in CLL patients than control 
healthy subjects and correlate with some unfavourable prognostic factors, like high 
lymphocyte count, advanced clinical stage or high serum levels of ǃ2-microglobulin (Molica 
et al., 1998). Antigen CD30 is typical of Hodgkin lymphoma and hairy cell leukemia variant, 
but in contrast to normal lymphocytes, it is also detectable at low density on CLL cells.  
TNF-R1 is expressed neither on malignant nor on normal B lymphocytes, while TNF-R2 is 
detected on both, although without significant differences between them (Trentin et al., 
1997). 
Not only TNF superfamily receptors regulate the survival of malignant lymphocytes. CD38 
is a glycoprotein mediating cell to cell interactions and acting as an adhesion molecule, with 
a reliable negative prognostic value for CLL patients. In vitro observations show that 
activation of CD38 by its ligand CD31 induces proliferation and differentiation of CLL cells 
and impairs their apoptosis by influence on the expression of numerous proteins of Bcl-2 
family, like Bax, Bim, Puma or Mcl-1 (Deaglio et al., 2010). Similar effect is exerted by CD100 
activation with plexin-B1. Since nurse-like cells from lymphoid tissue produce both ligands 
– CD31 and plexin B1, this phenomenon evidences the importance of environmental factors 
for CLL cells viability (Deaglio et al., 2005). 
2.3 Influence of chemokines on the survival of CLL cells 
Trafficking and homing of leukemic cells in a favourable microenvironment gives them an 
opportunity to benefit from a set of prosurvival factors secreted there. CXCL12, belonging to 
CXC chemokines and improving leukemic lymphocytes viability through induction of 
mitogen-activated protein kinases (MAPK or ERK 1/2) is one of them (Burger et al., 2000). 
However survival of CLL cells cultured in vitro together with nurse-like cells is significantly 
longer than those cultured only with a solution of CXCL12 (Burger et al., 2000), so it is 
supposed, that other substances produced by nurse-like cells influences the viability of 
malignant lymphocytes. Currently it is thought, that this role is played by two members of 
TNF superfamily: APRIL (a proliferation inducing ligand) and BAFF (B-cell activating factor 
of a TNF family), otherwise called BLyS (B lymphocyte stimulator). They are important 
survival and maturation factors of normal B lymphocytes (Mackay et al., 2003), probably 
influencing the expression of Bcl-2 family members (Craxton et al., 2005). After secretion by 
nurse-like cells, they support CLL cells survival in a paracrine manner, independently from 
CXCL12, through activation of NF-κB pathway, inhibiting both: spontaneous and drug-
induced apoptosis (Nishio et al., 2005). Moreover, neoplastic lymphocytes also express 
BAFF and APRIL, probably enhancing their own viability in an autocrine way (Kern et al., 
2004). 
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A number of studies conducted in vitro showed an influence of interleukins on  
a programmed cell death and survival of malignant CLL cells. Interleukin 1, nonspecific 
inflammatory mediator and lymphocytes activating factor, protects leukemic lymphocytes 
from apoptosis, spontaneous as well as induced by glucocorticosteroids (Jewell et al., 1995). 
Interleukin 2, the principal growth factor for T lymphocytes, inhibits the apoptosis of CLL cells 
by enhancing Mcl-1, Bcl-xL and survivin expression. Activated lymphocytes respond to this 
interleukin stronger then resting ones. Interestingly, at the same time interleukin 2 reduces the 
expression of Bcl-2, but global result of its activity on CLL lymphocytes remains prosurvival 
(Decker et al., 2010). Interleukin 4, produced by T helper cells, activates normal B lymphocytes 
and suppresses the apoptosis of leukemic cells through upregulation of Bcl-2 expression 
(Panayiotidis et al., 1993). Interleukin 5, a growth factor involved in hematopoiesis, which 
principal function is to stimulate the eosinophils maturation, increases spontaneous apoptosis 
rate of malignant lymphocytes in vitro in an unknown way, without influence on Bcl-2 
expression (Mainou-Fowler et al., 1994). Interleukin 6 is an important factor of growth and 
differentiation of B lymphocytes. It is thought to inhibit the programmed CLL cells death by 
increasing the Bcl-2 levels. Moreover, higher expression of interleukin 6 correlates with more 
advanced stage of the disease and higher serum concentration of ǃ2-microglobulin (Lai et al., 
2002). Physiological function of interleukin 8 is the induction of chemotaxis. In malignant 
lymphocytes it upregulates expression of Bcl-2, thus preventing their apoptosis. It is produced 
mainly by macrophages, but also CLL cells release it into the serum, thus exerting regulatory 
function on their own clone in an autocrine manner. Approximately a quarter of all CLL 
patients express abnormally high levels of interleukin 8, what correlates with a higher risk of 
the disease progression independently from an initial tumor burden (Molica et al., 1999). 
Interleukin 10 is overexpressed in malignant cells of some CLL patients and correlates with an 
aggressive course of the disease and short overall survival (Fayad et al., 2001). This probably 
results from its impact on neoplastic lymphocytes cell cycle, because inhibition of interleukin 
10 transcription leads to the enhanced apoptosis of the cells of a murine CLL model (Yen 
Chong et al., 2001). Interleukin 13, another cytokine involved in B lymphocytes activation, 
impedes leukemic cells apoptosis induced by interleukin 2 in vitro (Chaouchi et al., 1996). 
Interleukin 24 triggers apoptosis in CLL cells recruited to the cell cycle, by the inactivation of 
STAT3 kinase thus stabilizing expression of p53 (Sainz-Perez et al., 2008). 
3. Cell proliferation 
As mentioned at the beginning, CLL is traditionally considered as a result of inhibition of in 
vivo apoptosis. A wide variety of disturbances in CLL lymphocytes apoptosis was a subject 
of earlier sections of this chapter. There are numerous additional evidences supporting this 
opinion through demonstration of a weak proliferative potential of CLL cells. Low DNA 
content assessed by flow cytometry, low expression of Ki-67 and PCNA (proliferating cell 
nuclear antigen) – proteins associated with a nuclear proliferation, finally low rates of BrdU 
(bromodeoxyuridine) or 3H-thymidine incorporation – assays estimating the extent of DNA 
synthesis, are similar as in quiescent lymphocytes, what suggests arrest of leukemic cells in 
G0 phase of a cell cycle (Caligaris-Cappio & Hamblin, 1999). However there have been 
several studies published in recent years, supporting the hypothesis, that malignant clone of 
CLL comprises cells which are recruited to a proliferation cycle but arrested in its G1 phase 
(Damle et al., 2010), and that a small but significant fraction of all leukemic cells proliferates 
with measurable birth rates (Chiorazzi, 2007). 
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3.1 Proliferation centers 
Numerous studies showed that proliferation rate of CLL lymphocytes is not the same in 
each organ and compartment, but cells with higher birth rate accumulate in specific 
structures of a bone marrow and lymphatic nodes called pseudofollicles or proliferation 
centers, composed of lymphocytes, prolymphocytes and paraimmunoblasts of a neoplastic 
clone, with accompanying follicular dendritic cells, mesenchymal stromal cells and CD4-
positive T lymphocytes, where CLL cells have optimal microenvironmental conditions for 
growth and dividing (Caligaris-Cappio & Ghia, 2008). Malignant cells in those areas are 
characterized by a higher expression of Ki-67, CD71, CD38, MUM1/IRF-4 and coexpression 
of survivin and Bcl-2, factors typically associated with proliferation (Soma et al., 2006). 
Features of proliferation centers have a clear influence on the course of the disease. Patients 
with larger, confluent pseudofollicles estimated histopathologically in lymphatic nodes, 
with higher mitotic index and higher Ki-67 expression measured in these areas, more often 
suffer from the aggressive form of the disease and have significantly shorter overall survival 
(Gine et al., 2010). Furthermore it is suggested, that pseudofollicles accumulate CLL cells 
with genetic alterations (Balogh et al., 2011). Estimation of proliferation centers in bone 
marrow is possible rather in early stages of the disease, because in more advanced stages 
trephine biopsy often reveals diffuse pattern of a bone marrow infiltration, another well 
known negative prognostic factor in CLL, with faded structure of pseudofollicles (Mauro et 
al., 1994).  
3.2 Cell cycle regulatory proteins 
The important evidences in favour of CLL cells recruitment to a cell cycle were obtained 
from investigations concerning family of serine-threonine kinases called cyclin dependent 
kinases (cdk). Their appearance in cytosol and activation in precisely fixed phases of a cell-
division cycle by junction with regulatory subunits called cyclins is crucial for a proper 
course of DNA replication and mitosis. In the beginning of G1 phase cdk4 and cdk6 bind to 
cyclin D and phosphorylate the retinoblastoma protein (pRb), what activates transcription 
factors of E2F family and initiates transcription of proteins participating in DNA replication. 
Thereafter the association of cdk2 with cyclin E is fundamental for beginning of S phase 
(Sanchez & Dynlacht, 2005). It is reported, that significant number of malignant 
lymphocytes express several cyclins and cdks normally present in early G1 cell cycle phase. 
The increased levels of cdk4 and cyclin E were observed in CLL cells (Wołowiec et al., 1995; 
Korz et al., 2002) and higher expression of cdk4 was associated with presence of 17p or 11q 
deletions (Winkler et al., 2010). Aberrations of cellular content of cyclin D were also reported 
in leukemic lymphocytes. There are three known subtypes of this cyclin – D1, D2 and D3. 
Cyclin D3 is definitely overexpressed in CLL cells, what is confirmed by detection of its 
mRNA (Paul et al., 2005), as well as by the detection of its protein (Wołowiec et al., 2001). 
Studies concerning cyclin D2 are more discordant, with observations confirming the 
overexpression of the protein’s mRNA (Delmer et al., 1995) and denying it (Paul et al., 2005), 
while intracellular content of cyclin D2 is elevated comparing to normal B lymphocytes 
(Wołowiec et al., 2001). Even cyclin E, appearing later in G1 phase than cyclin D, is 
detectable in a significant subset of leukemic cells derived from peripheral blood (Decker et 
al., 2004) and from lymphatic nodes (Obermann et al., 2007). Expression of minichromosome 
maintenance protein 2 (Mcm-2) is a novel marker of cycling cells since this protein is 
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detectable from the beginning of G1 phase, earlier than Ki-67 expression. A significant 
subpopulation of CLL lymphocytes are Mcm-2 positive and Ki-67 negative, what brings 
additional evidence for their arrest rather in early G1, than G0 cell cycle phase (Obermann et 
al., 2007). Protein p27Kip1 is an inhibitor of the majority of known cdk – cyclin complexes, 
thus regarded as an important antiproliferative factor. CLL cells were demonstrated to 
express it in higher quantity than normal B lymphocytes and some studies suggested the 
relationship between higher p27Kip1 expression and impaired in vitro apoptosis of leukemic 
cells, although mechanism of this protein antiapoptotic activity in these cells remained 
unknown (Vrhovac et al., 1998). Other observations carried out on early and intermediate 
stage patients did not confirm this connection, nevertheless they revealed negative 
prognostic significance of high p27Kip1 expression in CLL, contrary to the majority of non-
hematological malignancies (Wołowiec et al., 2009). 
3.3 Telomeres length and DNA synthesis in vivo 
Investigations concerning telomeres brought another rationale for proliferation activity of 
CLL cells. Physiologically DNA composes long, repetitive sequences at the end of every 
chromosome: these structures are named telomeres. Their function is to protect cells from 
loss of information-coding segments of DNA during replication, when erosion of a genetic 
material on chromosomes ends takes place. After replication, an enzyme called telomerase 
restores lost fragments of telomeres, but only partially, what leads to gradual shortening of 
telomeres as a part of physiological aging. Therefore telomerase activation and shortening in 
telomeres length calculated proportionally to age are helpful markers of a cell proliferation 
(O’Sullivan & Karlseder, 2010). CLL lymphocytes are characterized by shorter telomeres and 
higher telomerase activity than normal B lymphocytes, what indicates on a greater number 
of their divisions in the past (Damle et al., 2004). Additionally, shorter telomeres are 
associated with genetic aberrations of defavourable prognostic signification, mainly 
unmutated status of the immunoglobulin heavy chain variable gene (Roos et al., 2008), and 
correlate with shorter progression-free and overall survival of CLL patients (Sellmann et al., 
2011). These observations lead to a possible conclusion, that shorter lymphocyte doubling 
time – well known marker of the aggressive course of the disease – results from higher 
proliferation rate of neoplastic cells. 
Recently designed technique measuring incorporation of deuterium (2H) from heavy water 
(2H2O), or deuterated glucose into deoxyribose molecules allows to calculate DNA synthesis 
and proliferation rate of dividing cells in vivo with much higher sensitivity than classic 
methods like Ki-67 expression or 3H-thymidine incorporation (Busch et al., 2007). Used in 
CLL, this technique also revealed that malignant cells have measurable birth rates (Messmer 
et al., 2005), and that among whole population of CLL lymphocytes, those expressing CD38 
have significantly higher proliferation rate comparing to CD38-negative cells (Calissano et 
al., 2009). 
4. Summary and therapeutic implications 
Although more and more is known about numerous anomalies of CLL cells apoptosis and 
proliferation, our knowledge still remains incomplete. Decades of research proved the 
crucial role of these disturbances in the appearance and clinical course of the disease, raising 
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hope, that their pharmaceutical corrections may evoke normal apoptosis of malignant cells, 
thus restraining CLL progression. Indeed, a lot of molecules, which influence signalling 
pathways regulating programmed cell death, are currently investigated towards their 
usefulness in a treatment of the disease (Robak, 2010). Nevertheless, a tremendous 
heterogeneity of CLL clinical course suggests significant differences of apoptosis and 
proliferation anomalies among individual patients, so probably no universal drug, efficient 
in every case, should be expected. 
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